What is the recommended starting dose and titration schedule of Synthroid (levothyroxine) for an adult without known cardiac disease?

Synthroid (Levothyroxine) Dosing for Adults Without Cardiac Disease

For adults under 70 years without cardiac disease, start levothyroxine at the full replacement dose of approximately 1.6 mcg/kg/day, then titrate by 12.5–25 mcg increments every 6–8 weeks based on TSH until the patient is clinically euthyroid and TSH normalizes to 0.5–4.5 mIU/L. 1, 2

---

Initial Dosing Strategy

Full Replacement Approach for Low-Risk Adults

• Start at 1.6 mcg/kg/day for patients younger than 70 years who have no cardiac disease or multiple comorbidities 1, 2
• This typically translates to 75–100 mcg/day for women and 100–150 mcg/day for men 3
• The full replacement dose can be initiated immediately without gradual titration in this population, as they tolerate rapid normalization of thyroid function 1, 3

Conservative Approach for Higher-Risk Adults

• Start at 25–50 mcg/day for patients over 70 years or those with any cardiac disease, atrial fibrillation risk, or multiple comorbidities 1, 2
• Use the lower starting dose even if the patient does not have overt cardiac disease but has risk factors such as hypertension, diabetes, or obesity 1

---

Titration Schedule

Standard Titration Protocol

• Increase the dose by 12.5–25 mcg increments every 6–8 weeks based on TSH response 1, 2
• Larger increments (25 mcg) are appropriate for younger patients without cardiac disease 1
• Smaller increments (12.5 mcg) should be used for elderly patients or those with any cardiac concerns 1

Monitoring Timeline

• Recheck TSH and free T4 every 6–8 weeks during dose titration, as this represents the time needed to reach steady-state concentrations 1, 2
• Do not adjust doses more frequently than every 6–8 weeks, as premature adjustments before steady state is reached can lead to inappropriate dosing 1
• The peak therapeutic effect of a given dose may not be attained for 4–6 weeks 2

---

Target Goals

Laboratory Targets

• TSH: 0.5–4.5 mIU/L with normal free T4 for primary hypothyroidism 1, 2
• Free T4 levels typically end up in the upper half of the normal reference range during adequate replacement therapy 1, 4
• For secondary or tertiary hypothyroidism, TSH is unreliable; instead, titrate to free T4 in the upper half of normal range and clinical euthyroidism 2

Clinical Targets

• Resolution of hypothyroid symptoms (fatigue, weight gain, cold intolerance, constipation) 1
• Normalization of cardiovascular function and lipid profile 1

---

Critical Safety Considerations

Pre-Treatment Assessment

• Rule out adrenal insufficiency before starting levothyroxine, especially in suspected central hypothyroidism, by checking morning cortisol and ACTH 1
• If adrenal insufficiency is present, start hydrocortisone at least one week before levothyroxine to prevent adrenal crisis 1
• Starting thyroid hormone before adequate glucocorticoid coverage can precipitate life-threatening adrenal decompensation 1

Administration Instructions

• Take on an empty stomach, 30–60 minutes before breakfast for optimal absorption 1, 5
• Separate from other medications by at least 4 hours, particularly iron, calcium supplements, antacids, and proton pump inhibitors 1, 5
• Absorption may be impaired by medications that increase gastric pH 5

---

Long-Term Monitoring

Maintenance Phase

• Once TSH is stable in the target range, recheck TSH every 6–12 months 1, 2
• Monitor sooner if symptoms change, new medications are started, or significant weight changes occur 1
• Free T4 can help interpret ongoing abnormal TSH levels during therapy, as TSH may take longer to normalize 1

---

Common Pitfalls to Avoid

Overtreatment Risks

• Approximately 25% of patients on levothyroxine are unintentionally overtreated with TSH suppression below 0.1 mIU/L 1
• TSH suppression increases risk of atrial fibrillation (3–5 fold), osteoporosis, fractures, and cardiovascular mortality, especially in patients over 60 years 1, 6
• If TSH falls below 0.1 mIU/L, reduce dose by 25–50 mcg immediately; for TSH 0.1–0.45 mIU/L, reduce by 12.5–25 mcg 1

Undertreatment Risks

• Persistent hypothyroid symptoms, adverse cardiovascular function, abnormal lipid metabolism, and reduced quality of life 1
• Inadequate treatment is associated with increased risk of heart failure and cardiovascular events 1

Dosing Errors

• Adjusting doses too frequently before steady state (waiting less than 6–8 weeks between adjustments) 1
• Failing to confirm elevated TSH with repeat testing, as 30–60% of elevated values normalize spontaneously 1, 7
• Starting full replacement dose in elderly or cardiac patients, which can unmask ischemia or precipitate arrhythmias 1, 2